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Abstract: Extracellular vesicles (EVs) are important components of the metastatic niche and are crucial
in infiltration, metastasis, and immune tolerance processes during tumorigenesis. We hypothesized
that human endogenous retroviruses (HERV) positive EVs derived from tumor cellsmay have a role in
modulating the innate immune response. The study was conducted in two different colorectal cancer
cell lines, representing different stages of cancer development: Caco-2, derived from a non-metastatic
colorectal adenocarcinoma, and SK-CO-1, derived from metastatic colorectal adenocarcinoma (ascites).
Both cell lines were treated with decitabine to induce global hypomethylation and to reactivate
HERV expression. EVs were quantified by nanoparticle tracking analysis, and HERV-positive EV
concentrations were measured by flow cytometry. The effect of EVs isolated from both untreated and
decitabine-treated cells on the innate immune response was evaluated by injecting them in zebrafish
embryos and then assessing Interleukin 1β (IL1-β), Interleukin 10 (IL-10), and the myeloperoxidase
(mpx) expression levels by real-time qPCR. Interestingly, HERV-K positive EVs concentrations were
significantly associated with a reduced expression of IL1-β and mpx, supporting our hypothesis that
HERV-positive EVs may act as immunomodulators in tumor progression. The obtained results open
new perspectives about the modulation of the immune response in cancer therapy.
Keywords: extracellular vesicles; HERV; innate immune response; zebrafish
1. Introduction
Tumor cells proliferate, infiltrate, and metastasize by forming a metastatic niche that can be
defined as a supportive and receptive microenvironment, which evades the surveillance by the immune
system [1–3]. Malignant cells apply several immune evasion strategies, and emerging data suggest
that an important role is exerted by the tumor-induced modulation of the innate immune system [4].
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The key components in the crosstalk between cancer and the surrounding microenvironment
include tumor-derived secreted factors, bone marrow-derived cells, suppressive immune cells, host
stromal cells, and extracellular vesicles (EVs) [5]. In particular, EVs have a recognized role in promoting
tumor progression, in inducing normal cell transformation, in remodeling the parenchymal tissue,
and in modulating the immune system [6,7].
Several membrane-bound determinants of tumor-derived EVs are involved in cancer infiltration
and in immune tolerance. Among these, a growing interest has been turned to human endogenous
retroviruses (HERVs) [8–10]. About 8.5% of the human genome consists of HERV genes, and they are
currently classified according to the first letter of the tRNA amino acid core of the primary binding
site, which starts reverse transcription. Their genomic structure shares similarities with known
exogenous retroviruses, as it consists of gag, pro, pol, and env genes, flanked by two long terminal
repeats (LTR) that act as promoters [11,12]. HERVs are involved in several physiological processes,
such as trophoblast fusion during placental development [13,14] and modulation of the immune
response [15,16]. However, these crucial functions may turn pathological and be implicated in the
development of different types of human cancers, such as breast cancer, lung cancer, prostate cancer,
testicular cancer, seminoma, hepatocellular carcinoma, colorectal cancer, melanomas, germ cell tumor
leukemia, and lymphoma [12,17–21]. The mechanisms underlying this evidence are still unclear,
but the transactivation of HERVs is supposed to promote carcinogenesis, either by directly effecting
HERV components (i.e., mRNAs or functional proteins), or by indirectly activating tumor-associated
genes [22,23]. HERV promoters are normally forced into a repressed state by DNA methylation [24,25],
but can be switched on (e.g., in response to environmental stimuli or viral infections), eventually acting
as triggers of an immune modulatory cascade. Moreover, some HERVs (e.g., HERV-K and HERV-H)
have been detected in the blood and tissues of patients with cancer [26,27]. In particular, HERVs are
involved in colorectal cancer tumorigenesis [28–32].
In the present study, we investigated the hypothesis that EVs derived from colorectal cancer cell
lines are involved in the modulation of the innate immune response, which is a central step in the
formation of the metastatic niche. We conducted our experiments in two different colorectal cancer
cell lines, which represented two different stages in cancer development: Caco-2, derived from a
non-metastatic epithelial colorectal adenocarcinoma; SK-CO-1, derived from a metastatic colorectal
adenocarcinoma (ascites). We focused on the role of HERV-positive EVs (i.e., HERV-K, HERV-W) as
possible immune-modulators. Therefore, we treated both colorectal cancer cell lines with decitabine,
in order to induce a global hypomethylation and reactivate HERVs expression. We further evaluated
the cellular production of total EVs and HERV-positive EVs and, finally, tested their effect on innate
immune response, by injecting them in zebrafish embryos. This model is suitable for studying this
mechanism because the adaptive immune system has not yet developed in the first month of life [33].
2. Results
2.1. HERV Methylation Analysis
We quantified the methylation levels of HERV-H, HERV-K, HERV-W, and HERV-P LTRs, and
observed that the Caco-2 cell line showed significantly higher baseline methylation levels compared
to the SK-CO-1 cell line for all the HERV genes analyzed, while the LINE-1 methylations levels,
representative of global methylation, were similar for both cell lines (Table 1). In order to increase
the HERVs expression, we treated the Caco-2 and SK-CO-1 cell lines with the hypomethylating agent
decitabine. As expected, the treatment induced a significant hypomethylation of LINE-1 sequences
(Supplementary Figure S1), both in the Caco-2 (untreated: mean ± standard deviation (SD) = 56.9 ± 3.3;
treated: mean± SD = 33.8± 0.6; p-value < 0.001) and in the SK-CO-1 (untreated: mean ± SD = 51.5 ± 1.6;
treated: mean ± SD = 38.7 ± 2.8; p-value < 0.001) cells.
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Table 1. Association of HERV LTRs methylation between untreated Caco-2 and SK-CO-1 cell lines.
T-test and Wilcoxon p-values in bold are statistically significant.
Element Cell Type Mean StandardDeviation Median
Interquartile
Range T-Test Wilcoxon
HERV K
Caco-2 54.6 1.6 55.5 2.9
0.016 0.036SK-CO-1 45.5 5.3 43.3 0.8
HERV W
Caco-2 92.9 1.1 93.2 1.6
0.014 0.095SK-CO-1 88.4 3.0 87.1 0.7
HERV H
Caco-2 69.9 2.4 70.1 3.3
<0.001 0.020SK-CO-1 16.5 2.6 17.3 3.7
HERV P
Caco-2 57.0 0.8 93.2 1.6
<0.001 0.019SK-CO-1 5.2 2.0 87.1 0.7
LINE1
Caco-2 56.9 2.3 56.6 1.0
0.002 0.012SK-CO-1 51.5 1.6 50.8 0.8
Moreover, decitabine induced a profound hypomethylation of HERV LTRs in both cell lines
(Figure 1; Table 2). The difference in methylation between treated and untreated cells was significant for
all the HERV LTRs analyzed, except for the HERV-H and HERV-P LTRs in the SK-CO-1 cells, although
this observation might be due to their extremely low basal methylation level.
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Figure 1. Spaghetti plot and box plot of HERV-H, HERV-K, HERV-W, and HERV-P LTRs methylation
levels (%5mC) in untreated and treated Caco-2 and SK-CO-1 cells.
To further characterize the functional effects of hypomethylation due to decitabine treatment,
HERV (Figure 2) env expression levels were evaluated by qPCR in both cell lines. In the Caco-2 cell
line, only HERV-H expression was significantly higher following decitabine treatment (p < 0.001)
(Figure 2, Supplementary Table S1), but HERV-K and HERV-W also showed a tendency toward increased
expression levels. In the SK-CO-1 cell line, the expression levels of all investigated HERV genes
were significantly increased between untreated and decitabine-treated cells (Figure 2, Supplementary
Table S1).
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Table 2. Association of HERV LTRs methylation between untreated- and decitabine-treated- Caco-2
and SK-CO-1 cells. T-test and Wilcoxon p-values in bold are statistically significant.
Caco-2 Cells
Element Treatment Mean StandardDeviation Median
Interquartile
Range T-Test Wilcoxon
HERV-K
Untreated 54.6 1.6 55.5 2.9
<0.001 0.012Treated 30.0 1.3 30.5 0.9
HERV-W
Untreated 92.9 1.1 93.2 1.6
<0.001 0.012Treated 64.1 3.0 63.2 63.2
HERV-H
Untreated 69.9 2.4 70.1 3.3
<0.001 0.012Treated 42.9 1.5 43.5 2.1
HERV-P
Untreated 57.0 0.8 56.8 1.3
<0.001 0.012Treated 29.6 1.9 29.2 1.3
SK-CO-1 Cells
Element Treatment Mean StandardDeviation Median
Interquartile
Range T-Test Wilcoxon
HERV-K
Untreated 45.5 5.3 43.3 0.8
<0.001 0.012Treated 30.8 2.8 29.9 0.4
HERV-W
Untreated 88.4 3.0 87.1 0.7
<0.001 0.012Treated 65.2 6.7 67.5 3.3
HERV-H
Untreated 16.5 2.6 17.3 3.7
0.210 0.312Treated 14.3 2.0 13.9 3.0
HERV-P
Untreated 5.2 2.0 5.0 3.4
0.137 0.183Treated 3.4 0.8 3.2 1.2Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 5 of 18 
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2.2. Evaluation and Characterization of EVs
We measured the concentration of EVs isolated from the untreated and decitabine-treated Caco-2
and SK-CO-1 cell lines by nanoparticles tracking analysis (NTA). We analyzed these values, comparing
decitabine-treated and untreated samples in terms of the mean release of exosomes (i.e., 30–130 nm EVs),
microvesicles (i.e., 130–700 nm EVs), and total EVs (i.e., 30–700 nm EVs) (Figure 3). We observed an
increase in total EVs release in the decitabine-treated Caco-2 cell line, with an average of 2.01 × 109/mL
(±4.71 × 109/mL), compared to the untreated, with an average of 1.47 × 109/mL (±3.69 × 109/mL)
(p = 0.05) (Figure 3).
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Figure 3. Spaghetti plot and box plot of number of extracellular vesicles (EVs) (count/mL × 106) derived
from untreated and decitabine-treated Caco-2 and SK-CO-1 cells.
No significant differences were detected between untreated and decitabine-treated SK-CO-1 cells
(Figure 3). We further analyzed the effect of decitabine treatment in terms of the distribution of mean
vesicle concentrations for each EV size. In the upper part of each panel of Figure 4A, we reported the
mean concentration for all EV sizes (i.e., from 30 to 700 nm). The comparisons among the EV sizes are
shown in Figure 4B, where the two p-values obtained, comparing decitabine-treated versus untreated
(Poisson linear regression models for repeated measures at each size), respectively, for the Caco-2 and
SK-CO-1 cells, were reported. EVs derived from Caco-2 cells were generally increased after decitabine
treatment; on the contrary, EVs from the SK-CO-1 cells were reduced.
Int. J. Mol. Sci. 2019, 20, 3669 6 of 17
Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 7 of 18 
 
 
Figure 4. A: Number of EVs (× 106) for each size (nm) from Caco-2 and SK-CO-1 cells. B: For each size, 
the p-value was reported from poisson regression models with repeated measures. 
We hypothesized that HERV-positive EVs may be involved in innate immune modulation. 
Therefore, the samples were further characterized for HERV-K and HERV-W positive EVs by flow 
cytometry analysis (Table 3).  
Table 3. Characterization of EV concentrations (count/mL) in Caco-2 an SK-CO1 cells. 
  Caco-2 SK-CO-1 
Treatment Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Untreated 
HERV-K 5.5 3.9 10.9 4.1 
HERV-W 9 3.4 13.3 4.5 
EpCAM 145.5 132.1 119.7 105.1 
CD63 131.7 173.2 34.7 25.1 
Treated 
HERV-K 9.1 6 8.3 4.1 
HERV-W 10.5 3.6 10.8 4.6 
EpCAM 204.6 184.2 81.4 58.5 
CD63 133.4 190.4 58.2 59.7 
Unfortunately, commercial antibodies against HERV-H and HERV-P are not currently available, 
therefore limiting our ability to explore these HERV-positive EVs subtypes. Since retroviruses share 
the same size of EVs, we evaluated the possibility of having a retroviral contamination in the EV 
pellet. Therefore, we measured HERV-W and HERV-K positive events in samples without gating for 
CFSE staining, and observed that HERV-K and HERV-W concentrations were the same in both cases 
(i.e., either gating or not for CFSE), as reported in the Supplementary Figure S2 for Caco-2 cells, and 
Supplementary Figure S3 for SK-CO-1 cells. Considering the subpopulations of EVs analyzed by 
high-resolution flow cytometry, these results minimize the possibility of pelleting HERV-W and 
HERV-K positive particles with dimensions ≥ 100 nm. 
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We hypothesized that HERV-positive EVs may be involved in innate immune modulation.
Therefore, the samples were further characterized for HERV-K and HERV-W positive EVs by flow
cytometry analysis (Table 3).
Table 3. Characterization of EV concentrations (count/mL) in Caco-2 an SK-CO1 cells.
Treatment
Caco-2 SK-CO-1
Mean StandardDeviation Mean
Standard
Deviation
Untreated
HERV-K 5.5 3.9 10.9 4.1
HERV-W 9 3.4 13.3 4.5
EpCAM 145.5 132.1 119.7 105.1
CD63 131.7 173.2 34.7 25.1
Treated
HERV-K 9.1 6 8.3 4.1
HERV-W 10.5 3.6 10.8 4.6
EpCAM 204.6 184.2 81.4 58.5
CD63 133.4 190.4 58.2 59.7
Unfortunately, commercial antibodies against HERV-H and HERV-P are not currently available,
therefore limiting our ability to explore these HERV-positive EVs subtypes. Since retroviruses share
the same size of EVs, we evaluated the possibility of having a retroviral contamination in the EV
pellet. Therefore, we measured HERV-W and HERV-K positive events in samples without gating
for CFSE staining, and observed that HERV-K and HERV-W concentrations were the same in both
cases (i.e., either gating or not for CFSE), as reported in the Supplementary Figure S2 for Caco-2 cells,
and Supplementary Figure S3 for SK-CO-1 cells. Considering the subpopulations of EVs analyzed
by high-resolution flow cytometry, these results minimize the possibility of pelleting HERV-W and
HERV-K positive particles with dimensions ≥ 100 nm.
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In both the untreated Caco-2 and SK-CO-1 cells, HERV-K and HERV-W positive EVs subtypes
were equally represented. Treatment with decitabine did not determine any significant variation in
HERVs-positive EVs concentrations (Supplementary Figure S4).
We also evaluated the epithelial cell adhesion molecule (EpCAM)-positive EVs, as EpCAM is an
epithelial cell marker, and therefore should be present in the total amount of microvesicles derived
from these cells. The release of EpCAM-positive EVs was higher for the Caco-2 cells than the SK-CO-1
cells (Table 3), thereby confirming the NTA observation. In addition, we quantified the tetraspanin
CD63 positive EVs as a non-tissue specific marker for EVs (Table 3) [34].
2.3. Effects on Innate Immune Response in Zebrafish Embryos
EVs derived from both the Caco-2 and SK-CO-1 cell lines were injected in the duct of Cuvier, and
therefore into the blood circulation, of embryos at 48 h post fertilization (hpf). Cell mediums Dulbecco’s
Modified Eagle’s Medium (DMEM) and Eagle’s Minimum Essential Medium (EMEM), for Caco-2 and
SK-CO-1 cells, respectively, were injected as control. For each treatment, 40–45 embryos were injected
and the experiment was repeated at least three-fold for each condition: control embryos, embryos
injected with the Caco-2 EVs, embryos injected with the SK-CO-1 EVs, and embryos injected with the
EVs derived from decitabine-treated Caco-2 and SK-CO-1 cells. Because zebrafish embryos only have
innate immunity during the first month of development, we were able to investigate the effect of EVs
on this specific immune component, while avoiding the confounding effect of the adaptive immune
system. To evaluate whether the EVs isolated from both the Caco-2 and SK-CO-1 untreated cells
might induce an immune reaction, we injected EVs and measured the expression of cytokines at 20 h
post injection (hpi). Specifically, we measured the pro-inflammatory cytokine Interleukin 1-β (IL1-β),
the anti-inflammatory cytokine Interleukin 10 (IL-10), and the myeloperoxidase (mpx) gene, ortholog of the
mammalian Mpo, and specific markers of granulocytes (Figure 5). We found that the expression of IL1-β
was significantly lower in embryos injected with EVs derived from the untreated Caco-2 (p = 0.034)
and the SK-CO-1 cells (p = 0.021), compared to those injected with control medium (Figure 5A,B). IL1-β
expression levels were also lower following the injection of EVs derived from decitabine-treated Caco-2
cells (p = 0.003), while no significant changes were observed for SK-CO-1 cells (Figure 5A,B). Therefore,
the results indicate a decrease in pro-inflammatory response following the injection of both Caco-2 and
SK-CO-1 EVs into zebrafish embryos. The anti-inflammatory response, measured in terms of IL-10
expression, was observed in parallel to the strong inactivation of the pro-inflammatory response, as in
the case of the injection of EVs derived from decitabine-treated Caco-2 cells (p < 0.001), and untreated
SK-CO-1-derived EVs (p = 0.012) (Figure 5C,D).
The expression of mpx, marking neutrophil activation, was not similar to IL-1β in untreated or
decitabine-treated Caco-2 cells (p = 0.035) and SK-CO-1 EVs injected cells (Figure 5E,F).
However, when we investigated the association between the concentration of total HERV-positive
EVs versus HERV-K or HERV-W positive EVs and IL1-β or mpx, we found that the concentration of
HERV-K positive EVs was inversely associated with the immune response, as measured by IL1-β gene
expression (HERV-K: β = −0.110; p = 0.013) and mpx (HERV-K: β = −0.110; p = 0.013) (Figure 6).
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and Eagle’s Minimum Essential Medium (EMEM), respectively), with EVs derived from untreated
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3. Discussion
EVs are fundamental components of the metastatic niche and are involved in infiltration, metastasis,
and immune tolerance processes during tumorigenesis. We hypothesized that HERV-positive EVs
derived from tumor cell lines may be involved in tumor progression and may mediate immune
tolerance. Therefore, we treated the two colorectal cancer cell lines Caco-2 and SK-CO-1, derived from
non- etastatic pith lial and metastatic a enocarcinomas, respectiv ly, with decitabine, to induce a
global hypomethylation and o ncrease HERV expression.
Although basal levels of LINE-1 methylation were similar in the Cac -2 and SK-CO-1 cells,
HERV LTR methylation was significantly higher in Caco-2 than in SK-CO-1 untreated cells. It is
well established that aberrant DNA methylation contributes to cancer development, and global
hypomethylation is generally correlated with tumor grades. Furthermore, DNA hypermethylation at
specific loci, in combination with repressive chromatin conformation, leads to the silencing of specific
genes involved in tumorigenesis [34,35]. The Caco-2 cell line is representative of a more differentiated
tumor grade, while SK-CO-1 is derived from a metastatic colorectal cancer characterized by lower
methylation levels of HERV LTRs (especially HERV-K and HERV-H LTRs), as they are involved in
tumor infiltration and metastasis [36]. As a matter of fact, HERV-K and HERV-H env expression levels
were also generally hig er in the SK-CO-1 cells than in t e ac -2 cells.
Decitabine treatment induced reduction of HERVs methylation levels and increased HERVs gene
expression. HERVs expression is often associated with cancer progression, and the expression of HERV-H
has been previously observed in colorectal cancer [31,37]. Interestingly, transcriptional differences
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in HERV-H elements between colon cancer and adjacent normal tissues have been reported, thereby
suggesting the active role that HERV-H plays in colorectal cancer tumorigenesis [30]. Moreover, HERV-H
mRNA was reported to be elevated in metastatic tumor cells undergoing epithelial-to-mesenchymal
transition [10]. HERV-H is not expressed in normal tissues, but is detected at high levels in cancer
cells [18]. In particular, HERV-H transcripts were reported to be selectively transcribed in about 60%
of colon cancers and in an even higher proportion of metastatic colon cancers [38]. Also, HERV-K is
transcriptionally silent in normal cells, and becomes active after malignant transformation. Furthermore,
increased expression of HERV-K has been detected in different human cancers, as well as HERV-P env,
which was reported to be significantly overexpressed in lung and breast cancer patients in comparison
to normal cases [26,27,39].
Although the Caco-2 and SK-CO-1 cells reacted similarly to decitabine treatment, by modulating
HERVs methylation and expression, our experiments showed that the two cell lines do not display
the same behavior in terms of EV release following decitabine treatment. The concentration of total
EVs derived from the Caco-2 cells was higher than that of the SK-CO-1 cells in both untreated and
decitabine-treated conditions. However, decitabine treatments determined an increase in EV release in
the Caco-2 cells, but a decrease in the SK-CO-1 cells. A possible speculation is that the two cell lines
are representative of two different cancer stages. While the Caco-2 cells are still partially differentiated
cells, and therefore represent a more precocious step of tumorigenesis, in which immunosuppression
is crucial for tumor survival, the SK-CO-1 cells have already reached the metastatic stage and might
have developed alternative strategies to counterbalance an immune response.
We further characterized EVs in order to quantify EpCAM, HERV-K, and HERV-W as membrane
determinants. EpCAM-positiveEVs were particularly high in the Caco-2 cells, confirming the
differentiated condition of this type of colorectal adenocarcinoma-derived-cell line. On the contrary,
in the SK-CO-1 cells, EpCAM-positive EV concentration was at low levels.
In order to investigate the effects of EVs derived from the Caco-2 and SK-CO-1 cells on innate
immunity, we took advantage of the zebrafish model. Indeed, zebrafish embryos have been gaining
favor as a powerful tool for the study of innate immunity [40]. In particular, the inflammatory response
following innate immunity activation has been demonstrated to occur in zebrafish through the release
of cytokines that are evolutionarily conserved in mammals [33,41]. The injection of EVs derived
from both Caco-2 and SK-CO-1 cells in zebrafish embryos significantly lowered the expression of the
pro-inflammatory cytokine IL1-β in comparison to embryos injected with control cell media, indicating
a role of EVs in modulating innate immune response. Therefore, to specifically evaluate the net effect
of HERV-positive EVs on the innate immune response in zebrafish, we considered the association
between HERV-K positive EV concentrations and expression levels of IL1-β or mpx. Interestingly,
we found a strong association between these two variables, thereby supporting our hypothesis that the
HERV-positive EVs might act as immunomodulators in tumor progression. Indeed, in the presence of
a robust block of pro-inflammation, EV injection generated an anti-inflammatory response, measured
in terms of an increase in IL-10 expression.
Although our observations are associative in nature, and will require further experimental
confirmations, the biological plausibility of our hypothesis is supported by HERV molecular features.
In fact, HERVs include an immunosuppressive domain in their transmembrane envelope proteins,
which may support tumor progression, abrogating the anti-oncogenic cytolytic immune response [42,43].
Moreover, the transmembrane subunit of a HERV-K env sequence was reported to inhibit T cell activation
in a similar way to that of the HIV virus, influencing cytokine release and immune gene expression [44].
The present study must be interpreted taking into account both its strength and limitations. To the
best of our knowledge, this was the first investigation describing the different steps from HERVs
hypomethylation, to cellular expression, to release in EVs, and to functional effect on innate immune
system. Therefore, our hypothesis is supported by different complementary approaches. Moreover,
this is one of the first papers describing the use of zebrafish embryos as a suitable model to investigate
the effects of EVs on conserved biological mechanisms.
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However, we are aware that only HERVs and EpCAM determinants were evaluated on the
surface of EVs, but the effects we observed on the immune response in zebrafish might be due to other
components, as we injected the total amount of EVs derived from cells. Nonetheless, we observed
a significant association between HERV-K positive EVs and a lower expression of IL1-β in zebrafish.
The effect seems to be not generalized, because no association was detected for HERV-W positive EVs.
Therefore, it is possible that HERV-W is not involved in this process, or at least not in the Caco-2 and
SK-CO-1 colorectal cancer cells.
Moreover, decitabine treatment hypomethylates not only HERVs and repetitive elements
(e.g., LINE-1), but also many other sequences. Therefore, it is possible that the effect of decitabine
treatment might be due to other reactivating components.
Future studies are needed to better characterize EVs derived from colorectal cancer cells also
for the other HERV families (i.e., HERV-H and HERV-P) following specific antibodies generation.
Moreover, a crucial perspective is to identify the mechanisms by which EVs, in particular those
carrying HERVs, promote immune tolerance. In order to confirm the immunomodulatory role of
HERV-positive EVs, in particular as regulators of innate immune response, the panel of investigated
cytokines should be further implemented and the involvement of immune cells should be better
defined. The characterization of the EV cargos will be pivotal in this context, as it will not only allow
for the identification of the specific molecular targeted pathways, but it will also open new perspectives
toward the modulation of immune response in cancer therapy.
4. Materials and Methods
4.1. Cell Cultures and Treatments
The human Caco-2 cell line (ATCC® HTB-37, Basel, Switzerland) was derived from the colorectal
adenocarcinoma of a 72-year old Caucasian male patient, while the SK-CO1 cell line (ATCC® HTB-39,
Basel, Switzerland) was derived from the metastatic site ascites, from a colorectal adenocarcinoma of
a 65-year old Caucasian male patient. The Caco-2 cell line was grown and sub-cultured in DMEM
medium (Sigma-Aldrich, St. Louis, MO, USA), while the SK-CO-1 cell line was grown and sub-cultured
in EMEM medium (Sigma-Aldrich, Germany), both containing L-glutamine (Sigma-Aldrich), 10% v/v
fetal bovine serum, and antibiotics (50 U/mL penicillin; 50 µg/mL streptomycin; Euroclone, Milan, Italy).
All cells were maintained in an incubator at 37 ◦C in a 5% CO2 humidified atmosphere. Decitabine
(5-Aza-2′-deoxycytidine, Sigma-Aldrich) treatments were performed at a final concentration of 5 µM,
96 h before harvesting the cells. For each condition, at least three independent experiments were
conducted. After each experiment, cells were cultured in serum-free media for 24 h before medium
collection and cell harvesting.
4.2. EVs Analysis
The isolation, purification, and characterization of EVs were performed by following the MISEV
2018 guidelines [45]. Detailed procedures and approaches are described in the Supplementary Materials
and Methods and in Supplementary Figures S5–S9.
4.3. Isolation and Purification of EVs
For the isolation of EVs shed by cell culture, 8 mL of medium was collected from each flask and
centrifuged at 1000, 2000, and 3000× g for 15 min at 4 ◦C. The obtained pellets were discarded to
remove cell debris. EVs were then isolated from supernatants by ultracentrifugation at 110,000× g for
4 h at 4 ◦C in polypropylene ultracentrifuge tubes (Beckman Coulter; Brea, CA, USA), filled with PBS
previously filtered through a 0.10 µm pore-size polyethersulfone filter (StericupRVP, Merck Millipore;
Burlington, MA, USA). To carry out nanoparticles tracking analysis (NTA) and flow cytometry, the
EV-rich pellet was resuspended in 500 µL of triple-filtered PBS.
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4.4. Nanoparticle Tracking Analysis (NTA) of EVs
Numbers and dimensions of EVs were assessed by NTA, using the NanoSight NS300 system
(Malvern Panalytical Ltd., Malvern, UK), as previously described [46], which measures the Brownian
motion of particles suspended in fluid and displays them in real time through a high sensitivity CCD
camera. Five 30 s recordings were made for each sample. Collected data were analyzed with NTA
software (Malvern Panalytical Ltd.), which provided high-resolution particle-size distribution profiles,
as well as measurements of the EV concentration.
4.5. High Resolution Flow Cytometry on EVs
EVs were characterized by high-resolution flow cytometry (MACSQuant, Miltenyi Biotec, Bergisch
Gladbach, Germany), according to the protocol for EV characterizations detailed in the Supplementary
Materials and Methods for high-resolution flow cytometry. Briefly, sample acquisition was performed
at the minimum speed flow (25 µL/min) using a MACSQuant Analyzer (Miltemyi Biotec). Sheath fluid
was filtered through 0.1 µm pore size filter to further improve the signal-to-noise ratio. The fluorescent
beads Fluoresbrite® YG Carboxylate Microspheres Size Range Kit I (0.1, 0.2, 0.5, 0.75, and 1 µm)
(Polysciences Inc, Warrington, Pennsylvania) was used to set the calibration gate in the FSC/FL1 and
FSC/SSC dot plots. Using a side scatter (SSC) threshold of 10 arbitrary units, the lower sensitivity
of the instrument was determined and the SSC and FITC voltages were set up. An overlap in the
100 nm beads population and the background noise was observed. In this way, it was possible to gate
the MVs ≥ 200 nm diameter. A total of 30 µL of sample was acquired on the MACSQuant Analyzer.
Event numbers, analyzed at a low flow rate and below 10,000 events/second, of equal sample volumes
were counted. Information about concentration (No. events/µL) was calculated by the analyzer
software. To verify the correctness of the count, we performed a serial dilutions measurement of
different EV samples. An r-value higher than 0.9 demonstrated the goodness of the experiment set up.
From these data we set the resuspending volume of 500 µL of PBS, resulting from the midpoint of the
standard curve.
To analyze cell culture media-isolated EV integrity, 60 µL aliquots were stained with 0.2 µM
5(6)-carboxyfluorescein diacetate N-succinimidyl ester (CFSE) at 37 ◦C for 20 min in the dark. In order
to assess the cellular origin of the EVs isolated from plasma, an immunophenotypization assay was
performed for each sample using a panel of specific antibodies: anti-HERV-K (clone 5i73) (USBiological,
Salem, MA, USA), anti-HERV-W (clone clone 4F10) (Sigma Aldrich), anti-CD326 (EpCAM)-APC (clone
HEA-125) (Miltenyi Biotec), anti-CD63 (clone-REA1055) (Miltenyi Biotec). Each antibody aliquot was
previously centrifuged at 17,000× g for 30 min at 4 ◦C to eliminate aggregates. A stained PBS control
sample was used to detect the autofluorescence of each antibody. Quantitative multiparameter analysis
of flow cytometry data was carried out using FlowJo Software (Tree Star, Inc.; Ashland, OR, USA).
Sample plots and gating for each antibody are shown in the Supplementary Figures S5–S9 for negative
control (i.e., triple-filtered PBS), Caco-2, and SK-CO-1 cells.
4.6. Methylation Analysis
DNA was isolated from 1 × 106 cells, using the QIamp DNA Mini Kit (Qiagen, Hilden, Germany),
following the manufacturer’s protocol. The analysis of DNA methylation was performed by following
previously published methods [47], with minor modifications. Briefly, a 50 µL PCR reaction was
carried out with 25 µL of Hot Start GoTaq Green Master mix (Promega, Madison, WI, USA), 1 pmol of
forward primer, 1 pmol of reverse primer, and 25 ng of bisulfite-treated genomic DNA. PCR cycling
conditions and primer sequences are provided in Supplementary Table S2. Biotin-labeled primers
(forward or reverse depending on the assay) were used to purify the final PCR product with Sepharose
beads. The PCR product was bound to Streptavidin Sepharose beads (Amersham Biosciences, Uppsala,
Sweden), purified, washed, denatured with 0.2 M NaOH, and washed again with the Pyrosequencing
Vacuum Prep Tool (Pyrosequencing, Inc., Westborough, MA, USA), according to the manufacturer’s
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instructions. Pyrosequencing primer (0.3 µM) was annealed to the purified single-stranded PCR
products, and pyrosequencing was performed with the PyroMark MD System (Pyrosequencing, Inc.,
Westborough, MA, USA). Methylation levels were expressed as the percentage of cytosines that were
methylated, determined as the number of methylated cytosines divided by the sum of methylated and
unmethylated cytosines, multiplied by 100% (% 5-methyl-Cytosine).
4.7. RNA Extraction form Caco-2 and SK-CO-1 Cells, Reverse Transcription-PCR, and Real-Time
Quantitative-PCR Assays (RT-qPCR)
RNA was isolated from 1 × 106 cells using the QIAmp RNA Blood Mini Kit (Qiagen, Hilden,
Germany), following the manufacturer’s protocol. One microgram of the total RNA was subjected
to reverse transcription using the QuantiTec Reverse Transcription Kit (Qiagen, Hilden, Germany).
Relative quantitative real-time PCR was performed to evaluate the expression levels of the HERV-H, -K,
-P, and -W env genes in a 7500 real-time PCR system (Applied Biosystem, CA, USA) using the QuantiTect
SYBR Green PCR kit (Qiagen, Hilden, Germany), according to the manufacturer’s instructions, with
the primer sets shown in Supplementary Table S2. Forty cycles were performed for each real-time
PCR assay, with the temperatures of annealing at 54 ◦C. All the samples were tested in triplicate
and were compared to the mean expression of the housekeeping genes glyceraldehyde 3-phosphate
dehydrogenase gene (GAPDH) and β-actin. Non-template controls were included for each primer
pair. The quantification of the RNA expression was performed using the comparative Ct method, and
the differences between the levels of env gene expression in the biological samples were calculated by
relative quantification (RQ).
4.8. Animals
Zebrafish (Danio rerio) embryos were raised and maintained according to international (EU
Directive 2010/63/EU) and national guidelines (Italian decree 4 March 2014, n.26) on the protection
of animals used for scientific purposes. The fish were maintained under standard conditions in the
fish facilities of Bioscience Dept, University of Milan, Via Celoria 26-20133 Milan, Italy (Aut. Prot,
n. 295/2012-A-20/12/2012). We expressed the embryonic ages in days post fertilization (dpf). Embryos
were collected by natural spawning, staged according to Kimmel and colleagues [48], and raised at
28 ◦C in fish water (Instant Ocean, 0.1% Methylene Blue) in Petri dishes, according to established
techniques. After 1 dpf, to prevent pigmentation 0.003% 1-phenyl-2-thiourea (PTU, Sigma-Aldrich,
Saint Louis, MO, USA) was added to the fish water. Embryos were washed, dechorionated, and
anaesthetized, with 0.016% tricaine (Ethyl 3-aminobenzoate methanesulfonate salt; Sigma-Aldrich),
before EV injection.
4.9. EVs Microinjections
Zebrafish embryos at 2 dpf were manually dechorionated and anaesthetized with 0.016% tricaine
(Ethyl 3-aminobenzoate methanesulfonate salt; Sigma-Aldrich). EVs derived from the Caco-2 and
SK-CO-1 lines were resuspended in PBS 1X and injected into the duct of Cuvier, to allow their delivery
in the circulation. A manual microinjector (Eppendorf, Germany) was used with glass microinjection
needles. Control embryos were injected with serum-free media (DMEM for Caco-2 and EMEM for
SK-CO1 cells). Following the injections, embryos were kept at 28 ◦C for 20 h, until their processing for
RNA extraction.
4.10. RNA Extraction form Zebrafish Embryos, Reverse Transcription-PCR, and RT-qPCR
Zebrafish embryos at 3 dpf (at least 30 embryos for each category), were collected for RNA extraction
using TRIZOL reagents (Life Technologies, Carlsbad, CA, USA) following the manufacturer’s protocol.
After DNase I RNase-free (Roche Diagnostics) treatment to avoid possible genomic contamination,
1 µg of RNA was reverse-transcribed using the “ImProm-II™ Reverse Transcription System” (Promega,
Madison, WI, USA) and a mixture of oligo(dT) and random primers, according to manufacturer’s
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instructions. RT-qPCRs were carried out in a total volume of 20 µL containing 1X iQ SYBR Green Super
Mix (Promega), using the proper amount of the RT reaction [49]. RT-qPCRs were performed using the
BioRad iCycler iQ Real-Time Detection System (BioRad, Hercules, CA, USA). The expression levels
of IL1-β were determined. qPCRs were performed using the BioRad iCycler iQ Real-Time Detection
System (BioRad, Hercules, CA, USA). Thermocycling conditions were 95 ◦C for 10 min, 95 ◦C for 10 s,
and 55 ◦C for 30 s. All reactions were performed in triplicate for 40 cycles. For normalization purposes,
rpl8 expression levels were tested in parallel with the gene of interest [50]. Primer sequences are
reported in Supplementary Table S2.
4.11. Statistical Analysis
Descriptive statistics were performed on all variables: continuous variables were expressed as the
mean ± standard deviation (SD) and the median with interquartile range (IQR). Spaghetti and box
plots were used to represent HERV LTR and LINE-1 methylation, HERVs expression levels, counts of
EVs, and of EVs subtypes, of untreated and decitabine-treated Caco-2 and SK-CO-1 cells. Spaghetti
and box plots were also used to represent experiments for IL1-β expression levels in zebrafish embryos
injected with control medium, with EVs derived from decitabine-treated and with cell lines (in both
Caco-2 and SK-CO-1).
Comparisons of HERV LTR methylation between the two cell types in untreated cells were
evaluated by t-test and validated by the Wilcoxon rank-sum test. The same approach was adopted to
compare untreated- and decitabine-treated cells in each cell line.
We analyzed the effect of decitabine treatments in terms of distribution of vesicle mean
concentrations for each EV size. Firstly, we estimated the EV mean concentration at each size,
with univariate Poisson linear regression models for repeated measures. Secondly, we compared the EV
mean differences between untreated and decitabine-treated cell lines. Results were reported as a series
graph for EV mean concentrations of each size and vertical bar charts to represent the size-specific
p-values obtained, comparing untreated- and decitabine-treated Caco-2 and SK-CO1 cells. For all the
graphs the X-axis was the size of EVs.
The association between the number of HERV-K and HERV-W positive EVs and IL1-β expression
levels in zebrafish embryos was investigated with linear regression models adjusted for cell lines
and treatment. All tests were two-sided, and a p-value < 0.05 was considered statistically significant.
Analyses were performed with SAS 9.4 software (SAS Institute Inc., Cary, NC, USA).
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/15/
3669/s1.
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